# The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer

> **NCT07638878** · — · ACTIVE_NOT_RECRUITING · sponsor: **Guangzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer (Locally Advanced or Metastatic)

## Interventions

- **DRUG:** tislelizumab in combination with nab-paclitaxel and platinum chemotherapy

## Key facts

- **NCT ID:** NCT07638878
- **Lead sponsor:** Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-06
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638878, "The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07638878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*